4 news items
RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040
RDHL
3 Jun 24
."
About Opaganib (ABC294640) Opaganib, a proprietary investigational
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
RDHL
6 May 24
)
Opaganib, a proprietary investigational host-directed and potentially broad-acting drug, is a first-in-class, orally administered sphingosine kinase-2 (SPHK2
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
RDHL
8 Apr 24
RedHill's R&D efforts are concentrated on its two lead investigational candidates, opaganib
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price
RDHL
2 Apr 24
requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under
- Prev
- 1
- Next